United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032
Overview
The United Arab Emirates Antibody Drug Conjugates (ADC) Market is expected to reach a 268.55 USD Million by 2032 and is projected to grow at a CAGR of 16.25% from 2025 to 2032.
United Arab Emirates Antibody Drug Conjugates (ADC) Market 2018-2032 USD Million
United Arab Emirates Antibody Drug Conjugates (ADC) Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 93.58 USD Million
- Projected Market Size (2032): 268.55 USD Million
- CAGR (2025-2032): 16.25%
Key Findings of United Arab Emirates Antibody Drug Conjugates (ADC) Market
- The United Arab Emirates Antibody Drug Conjugates (ADC) Market was valued at 268.55 USD Million in 2024.
- The United Arab Emirates Antibody Drug Conjugates (ADC) Market is likely to grow at a CAGR of 16.25% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Cleavable Linkers in Linkers Component Segment accounted for the largest share of the market with a revenue of 75.54 USD Million
- The fastest growing segment Ambulatory Centers in End User Segment grew Fastest with a CAGR of 17.47% during the forecast period from 2024 to 2032.
United Arab Emirates Antibody Drug Conjugates (ADC) Market Scope
- Others
- Genitourinary Cancer
- Gastrointestinal Cancer
- Gynecological Cancer
- Lung Cancer
- Blood Cancer (Leukemia, Lymphoma)
- Breast Cancer
- Chemical Conjugation
- Site-Specific Conjugation
- Disulfide Linkers
- Hydrazone Linkers
- Thioether Linkers
- Peptide Linkers
- Microtubule Disrupting Agents
- DNA Damaging Agents
- Home Healthcare
- Others
- Ambulatory Centers
- Clinics
- Specialty Center
- Hospitals
- Others
- Retail Sales
- Direct Tenders
- Tissue Factors
- CD33
- CD19
- Others
- CD22
- Nectin 4
- CD30
- CD79B
- Trop-2
- HER2 Receptor
- Others
- Tivdak
- Mylotarg
- Zylonta
- Elahere
- Besponsa
- Padcev
- Kadcyla
- Adcetris
- Polivy
- Trodelvy
- Enhertu
- Non Cleavable Linkers
- Cleavable Linkers
- First Generation ADCs
- Fourth Generation ADCs
- Second Generation ADCs
- Third Generation ADCs
United Arab Emirates Antibody Drug Conjugates (ADC) Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2023 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 93.58 USD Million |
| Market Value in 2032 | 268.55 USD Million |
| CAGR (2025-2032) | 16.25% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Indication,Conjugation Technology,Linker Technology,Cytotoxic Payloads or Warheads Component,End User,Distribution Channel,Antigen Component,Product,Linkers Component,Antibody Component |
Regional Insights:
-
Leading Market (2024-2032): United Arab Emirates, leading in terms of revenue 93.58 USD Million in 2024
- Key Country: United Arab Emirates, leading in terms of revenue with value of 93.58 USD Million in 2024.
Segments and Scope
-
United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032, By Indication
- Breast Cancer is the largest segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 43.44 USD Million in the year 2024.
- Breast Cancer is the Fastest growing segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 16.83 % in forecast period 2025-2032.
-
United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032, By Conjugation Technology
- Site-Specific Conjugation is the largest segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 55.45 USD Million in the year 2024.
- Site-Specific Conjugation is the Fastest growing segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 16.69 % in forecast period 2025-2032.
-
United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032, By Linker Technology
- Peptide Linkers is the largest segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 59.42 USD Million in the year 2024.
- Peptide Linkers is the Fastest growing segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 16.34 % in forecast period 2025-2032.
-
United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032, By Cytotoxic Payloads or Warheads Component
- DNA Damaging Agents is the largest segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 61.03 USD Million in the year 2024.
- DNA Damaging Agents is the Fastest growing segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 16.33 % in forecast period 2025-2032.
-
United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032, By End User
- Hospitals is the largest segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 58.55 USD Million in the year 2024.
- Ambulatory Centers is the Fastest growing segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 15.90 % in forecast period 2025-2032.
-
United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032, By Distribution Channel
- Direct Tenders is the largest segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 64.13 USD Million in the year 2024.
- Retail Sales is the Fastest growing segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 16.28 % in forecast period 2025-2032.
-
United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032, By Antigen Component
- HER2 Receptor is the largest segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 58.36 USD Million in the year 2024.
- HER2 Receptor is the Fastest growing segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 16.61 % in forecast period 2025-2032.
-
United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032, By Product
- Enhertu is the largest segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 64.84 USD Million in the year 2024.
- Enhertu is the Fastest growing segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 16.53 % in forecast period 2025-2032.
-
United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032, By Linkers Component
- Cleavable Linkers is the largest segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 75.54 USD Million in the year 2024.
- Cleavable Linkers is the Fastest growing segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 16.29 % in forecast period 2025-2032.
-
United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032, By Antibody Component
- Third Generation ADCs is the largest segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a revenue of 55.36 USD Million in the year 2024.
- Third Generation ADCs is the Fastest growing segment in United Arab Emirates Antibody Drug Conjugates (ADC) Market to 2032 with a Growth rate of 16.41 % in forecast period 2025-2032.
United Arab Emirates Antibody Drug Conjugates (ADC) Market Company Share Analysis
| Company Name |
|
||
| Takeda Pharmaceutical Company Limited | |||
| Astellas Pharma Inc. | |||
| Gilead Sciences, Inc. | |||
| DAIICHI SANKYO COMPANY, LIMITED | |||
| F. Hoffmann-La Roche Ltd. | |||
United Arab Emirates Antibody Drug Conjugates (ADC) Market Geographical Sales Distribution, 2018-2032 USD Million
United Arab Emirates Antibody Drug Conjugates (ADC) Market Company Profiling
Industry Related Reports
Frequently Asked Questions
Coming Soon....
United Arab Emirates Antibody Drug Conjugates (ADC) Market Scope
- Others
- Genitourinary Cancer
- Gastrointestinal Cancer
- Gynecological Cancer
- Lung Cancer
- Blood Cancer (Leukemia, Lymphoma)
- Breast Cancer
- Chemical Conjugation
- Site-Specific Conjugation
- Disulfide Linkers
- Hydrazone Linkers
- Thioether Linkers
- Peptide Linkers
- Microtubule Disrupting Agents
- DNA Damaging Agents
- Home Healthcare
- Others
- Ambulatory Centers
- Clinics
- Specialty Center
- Hospitals
- Others
- Retail Sales
- Direct Tenders
- Tissue Factors
- CD33
- CD19
- Others
- CD22
- Nectin 4
- CD30
- CD79B
- Trop-2
- HER2 Receptor
- Others
- Tivdak
- Mylotarg
- Zylonta
- Elahere
- Besponsa
- Padcev
- Kadcyla
- Adcetris
- Polivy
- Trodelvy
- Enhertu
- Non Cleavable Linkers
- Cleavable Linkers
- First Generation ADCs
- Fourth Generation ADCs
- Second Generation ADCs
- Third Generation ADCs
Frequently Asked Questions
United Arab Emirates Antibody Drug Conjugates (ADC) Market Company Profiling
Frequently Asked Questions
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.